Methadone and QTc Prolongation in Pain and Palliative Care Patients: A Case Control Study

Document Type

Poster Presentation

Publication Date



Methadone (ME) is commonly used in pain and palliative care (PPC) patients with refractory pain or intolerable opioid adverse effects (AEs). A unique ME AE is its QTc interval prolongation risk but most evidence exists in methadone maintenance therapy (MMT) patients. Our goal was to identify QTc interval prolongation risk factors in PPC patients receiving ME and other medications known to prolong the QTc interval and develop a risk stratification tool.



Presented at the American College of Clinical Pharmacy Global Conference on Clinical Pharmacy in San Francisco, California, October 2015.

Abstract published in Pharmacotherapy, Volume 35, Issue 11, Page e202, November 2015:

Additional Files